22.59% to Target, JP Morgan Cazenove Reaffirms Overweight Rating for Meggitt PLC (LON:MGGT) Stock; Rxi Pharmaceuticals (RXII) Shorts Increased By 14.87%

Rxi Pharmaceuticals Corporation (NASDAQ:RXII) had an increase of 14.87% in short interest. RXII’s SI was 194,700 shares in February as released by FINRA. Its up 14.87% from 169,500 shares previously. With 93,600 avg volume, 2 days are for Rxi Pharmaceuticals Corporation (NASDAQ:RXII)’s short sellers to cover RXII’s short positions. The SI to Rxi Pharmaceuticals Corporation’s float is 10.11%. The stock decreased 7.41% or $0.24 during the last trading session, reaching $3. About 115,911 shares traded. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since February 28, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.

In a research note revealed to clients and investors on Wednesday morning, Meggitt PLC (LON:MGGT) stock Overweight was reaffirmed at JP Morgan Cazenove. They currently have a GBX 540.00 TP on the stock. JP Morgan Cazenove’s TP suggests a potential upside of 22.59% from the company’s last price.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $7.11 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The companyÂ’s clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

Meggitt PLC designs and manufactures components and sub-systems for aerospace, defense, energy, medical, industrial, test, and automotive markets in the United Kingdom, rest of Europe, the United States, and internationally. The company has market cap of 3.53 billion GBP. It operates through Meggitt Aircraft Braking Systems, Meggitt Control Systems, Meggitt Polymers & Composites, Meggitt Sensing Systems, and Meggitt Equipment Group divisions. It has a 12.15 P/E ratio. The Meggitt Aircraft Braking Systems segment offers anti-skid, auto braking, brake-by-wire, and integrated brake metering/anti-skid brake control systems; carbon, rotor, electrically-actuated, and steel brakes; integrated tire pressure indicator systems/brake temperature monitoring systems; and landing gear computers, park/emergency valves, auto spoiler deployment, other braking system hydraulic components, main and nose wheels, and tire pressure monitoring systems.